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Topoisomerases are enzymes that modulate the topological struc-
ture of DNA in order to facilitate cellular events such as replica-
tion and transcription. This typically involves processes such as
supercoil relaxation or DNA unknotting and decatenation.
Eukaryotes possess two distinct classes of these enzymes, types I
and II. Type I enzymes function by cleaving a single DNA strand,
passing the other strand through the gap, and then resealing the
break. Type II enzymes function similarly, but cleave both DNA
strands, and pass through an entire helix. For a review see Wang
(1996).
DNA topoisomerases are known to be the targets of several
drugs widely used in cancer chemotherapy. Such drugs act as
cellular poisons by binding to, and trapping the DNA-enzyme
intermediate ‘cleavage complex’ on the DNA whilst one or more
DNA strands are broken. This leads to DNA fragmentation and
ultimately cell death, the likelihood of which is proportional to the
level of active enzyme. Hence such agents are often more effective
against proliferating cells.
Topoisomerase poisons are known to be type-specific – i.e. they
will target either type I or type II enzymes. Agents known to target
human topoisomerase I include camptothecin, and its related
family of compounds, including topotecan and irinotecan which
are used in chemotherapy for ovarian and colorectal cancers
(Kudelka et al, 1996; Rothenberg et al, 1996). Agents known to
target topoisomerase IIa and IIb include etoposide, teniposide,
daunorubicin and doxorubicin, which are used in therapy of
various leukaemias, lymphomas and breast cancer (Fisher et al,
1993; Devine and Larson, 1994; Harris et al, 1997).
The recently discovered human topoisomerase IIIa and b (type
I) enzymes represent further possible targets for topoisomerase
poisons. The gene encoding topoisomerase IIIa was discovered by
Hanai et al who localized it to chromosome 17p11.2–12 (Hanai et
al, 1996). The gene encoding topoisomerase IIIb was discovered
in 1997 as part of the immunoglobulin l gene locus at 22q11
(Kawasaki et al, 1997). Ng et al later discovered that there were
multiple transcripts of this gene (Ng et al, 1999); however very
little else is known about topoisomerase IIIb.
As yet, no investigations have been reported concerning the
potential of topoisomerase IIIa or IIIb as targets for anti-
neoplastic agents. Indeed little data is available regarding the
localization and expression of either isoform. Topoisomerase IIIa
has been found to be essential in early embryogenesis in mice,
where top3a–/– embryos were found to be non-viable (Li & Wang,
1998). Based on Northern analysis of topoisomerase IIIa mRNA,
it is suspected that enzyme is present in many different cell types
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Summary Topoisomerases are nuclear enzymes that modulate the topological structure of DNA in order to facilitate cellular events such as
replication and transcription. These enzymes are also the cellular targets of certain classes of chemotherapeutic agents termed
topoisomerase poisons. A new human topoisomerase isoform, IIIa, was discovered in 1996, which is thought to have roles in genome stability
and possibly chromosome separation during mitosis. It is possible that novel or existing anti-topoisomerase agents target topoisomerase IIIa,
suggesting that this enzyme may have potential as a prognostic marker and chemotherapeutic target. In order to study expression patterns of
topoisomerase IIIa we have produced a novel monoclonal antibody to human topoisomerase IIIa (TOPO3a-1A4), and used it to assess
topoisomerase IIIa expression in a wide range of normal and neoplastic tissues. We have found that topoisomerase IIIa is expressed in a wide
range of tissue types, with especially high concentrations in endothelial cells and stromal fibroblasts. No general relationship was observed
between expression of topoisomerase IIIa and proliferation. Expression in neoplastic tissues often paralleled their normal counterparts,
although certain tumours showed either increased (e.g. colonic adenoma) or reduced (e.g. gastric carcinoma, small cell carcinoma of
bronchus) expression. If topoisomerase IIIa is found to be a target for chemotherapeutic agents, clinical response in different tumour types
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doi: 10.1054/ bjoc.2000.1293, available online at http://www.idealibrary.com on (Fritz et al, 1997). Sequence tags have been obtained from cDNA
libraries derived from adult human heart (Waye et al, 1995) and
fetal spleen/liver, and cDNAs have been obtained from hepatoma
and T-cells (Hanai et al, 1996). It also seems that expression may
be differentially regulated in tissues such as testis (Seki et al,
1998) and also in a developmental manner as the enzyme has been
found to be essential in early embryogenesis (Li & Wang, 1998).
In order to study the precise cellular localization and tissue
distribution of human topoisomerase IIIa, we have produced the
monoclonal antibody TOPO3a-1A4 which can be used to detect
this enzyme in formalin-fixed paraffin-embedded tissue sections
and Western blots. We have assessed topoisomerase IIIa expres-
sion in a wide variety of tissue types, both normal and neoplastic,
and here we report our findings.
MATERIALS AND METHODS
Production of topoisomerase IIIa recombinant protein
After sequence analysis and comparison with other topoiso-
merases and proteins, it was decided to generate recombinant
protein corresponding to the C-terminal of the molecule. Specific
topoisomerase IIIa primers were designed and manufactured
using the phosphoramidite method. Total cellular RNA was
extracted from a HeLa cell line according to a modified method of
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987) and
was used as a template for reverse transcription using the antisense
primer (5¢GCTCGAGTCATCTGTTCTGAGGACAAAAGGG-
3¢). The resulting reaction mixture served as a substrate for 30
rounds of the polymerase chain reaction (PCR) using the sense
topoisomerase III primer (5¢-GCTCGAGATGGACAACAGC-
CAGCACCCC-3¢). The amplification of a 685 bp product was
confirmed by agarose gel electrophoresis prior to ligation into
pUC57/T (MBI Fermentas). Constructs were transformed into
Novablue E. coli, and transformants containing appropriately
sized inserts were identified by restriction digestion.
Topoisomerase IIIa-containing pUC constructs were expanded
and the insert excised and sub-cloned into appropriately CIP (calf-
intestinal phosphatase)-treated pET 15B expression vector
(Novagen). These subclones were re-transformed into T7 poly-
merase(–) Novablue cells, and transformants were expanded and
correctly orientated by restriction mapping. Selected constructs
were then re-transformed into T7 polymerase(+) BL21 E. coli.
Suspension cultures were then grown from colonies from selection
plates and protein expression induced by the addition of IPTG
(isopropyl thiogalactoside). Induced protein was found to be
expressed in the cytosol, with an approximate molecular weight of
25KDa upon analysis by SDS-PAGE electrophoresis. The poly-
histidine-tagged protein was then purified by Ni2+ chelation
column chromatography.
Hybridoma production
Recombinant protein was injected into five female Balb/c mice in
a series of 4 injections given at 14 day intervals. The first consisted
of 20 mg protein per mouse in Freunds complete adjuvant, injected
subcutaneously. The second was identical but in Freunds incom-
plete adjuvant. Third and fourth injections were in PBS and
administered intraperitoneally. Mice were intravenously boosted
with 60 mg of protein four days prior to fusion.
The spleen cells were fused with NS-1/Ag3 myeloma cells
using polyethylene glycol, and plated out into HAT-selective
growth medium. After 10 days, supernatants from each well were
assayed by enzyme-linked immunosorbent assay (ELISA) and
colonies showing reactivity were also tested by immunohisto-
chemistry. Specific antibody-secreting hybridomas were picked
and transferred to separate wells in a 24-well growth plate. After a
period of growth, cells were frozen down, and the supernatants
from these colonies screened by Western blotting. Positive lines
were subsequently cloned by double dilution, and re-assayed by
immunohistochemistry, before being subjected to a further three
rounds of cloning.
Production of a topoisomerase IIIb expression
construct
Recombinant DNA corresponding to human topoisomerase IIIb
was generated by PCR using the primers 3¢-AAGGAATTCAT-
GAAGACTGTGCTCATGGTT-5¢ and 3¢-CTCGGATCCTCAT-
CATACAAAGTAGGCGGC-5¢. This PCR product was then
cloned into the yeast expression vector pEG202 in frame with a
Lex-A moiety at EcoRI and BamHI sites. This construct was then
transformed into yeast strain EGY48.
Western blotting
Cell suspensions were solubilized in 2´ Laemmli sample buffer
(Laemmli, 1970) prior to boiling for 4 minutes. Lysate proteins
were then resolved by discontinuous SDS-PAGE using a 10%-T,
2.6%-C acrylamide/bis-acrylamide gel, before being transferred 
to Hybond C nitrocellulose paper (Amersham) using semi-dry
Western blot apparatus. The nitrocellulose was then blocked using
3% BSA made up in PBS-tween buffer (140 mM NaCl, 0.27 mM
KCl, 10 mM Na2HPO4, 1.8 mM NaH2PO4·H2O, 0.05% tween 20),
and subsequently incubated with TOPO3a-1A4 (1:100) or anti-
Lex A (Invitrogen) (1:5000) in PBS-tween for 90 minutes. After
washing, primary antibodies were detected using either peroxide-
conjugated rabbit anti-mouse antibody (DAKO) and one-
component peroxidase substrate solution (KPL), or by using the
‘SuperSignal’ kit (Pierce).
Immunohistochemistry and scoring
TOPO3a-1A4 was tested on paraffin-embedded sections using an
indirect strept-ABC method. Briefly, sections were de-waxed and
hydrated prior to blocking of endogenous peroxide using
methanol/hydrogen peroxide. Antigen retrieval was carried out at
high temperature and pressure using citrate buffer (200 mM citric
acid, 500 mM NaOH, pH 6.0). Sections were then washed in 1 ´
TBS (140 mM NaCl, 50 mM Tris/HCl pH 7.6) and blocked using
20% normal rabbit serum (NRS) (in 1 ´ TBS) for 10 minutes,
before incubation with TOPO3a-1A4 at 1:20 (in 20% NRS) for
one hour. After washing in TBS, sections were incubated with
biotinylated rabbit anti-mouse secondary antibody (DAKO) at
1:500 (in 20% NRS) for 30 minutes. After further washing, strep-
tavidin-biotin (DAKO) was added at 1:100 (in 20% NRS), and the
sections incubated for 30 minutes. The final reaction was visual-
ized using 3,3¢-diaminobenzidine (Sigma) in a TBS/hydrogen
peroxide solution for 3 minutes. Finally, sections were counter-
stained using Harris’ haematoxylin before being blued, and then
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microscope, cell types identified, and the proportion and intensity
of nuclear staining estimated. Intensity was assessed on a subjec-
tive scale of 0 = negative, + = positive, ++ = strong and +++ = very
strong staining.
Tissues
All tissues employed were routinely processed formalin-fixed
paraffin-embedded specimens retrieved from the archival files of
the Pathology Department, Royal Victoria Infirmary, Newcastle-
upon-Tyne, UK.
RESULTS
Antibody production
Recombinant protein was generated as described and used to
generate an immune response in mice. After the fusion and subse-
quent assay by ELISA, 120 colonies showed strong reactivity.
These supernatants were further screened on paraffin-embedded
tonsil sections and 20 colonies were picked and transferred to a
fresh 24-well plate. After a period of growth, Western blotting
revealed three lines secreting antibody that reacted with proteins
of roughly appropriate size. After cloning by double dilution, and
re-assay by immunohistochemistry, it was decided that two of
these lines showed some non-specific cross-reactivity. In contrast,
the remaining line proved highly specific and was subsequently
subjected to three rounds of cloning before being successfully re-
tested and employed on a panel of normal and pathological tissue
sections.
Antibody characterization by Western blotting
Analysis by Western blot (Figure 1) showed that TOPO3a-1A4
reacted with a protein of around 110 kDa in HT29 (colon
adenoma), T47D (breast carcinoma), A431 (epidermal carcinoma)
and SKBr3 (breast carcinoma) cell lysates, although there were
some faint additional smaller bands present, which have been
documented previously (Goulaouic et al, 1999). These may repre-
sent products of recently reported alternative transcripts of topo-
isomerase IIIa (Ng et al, 1999) or degradation products of the
topoisomerase IIIa protein. Cell lysates of ZR75 (breast carci-
noma), A549 (lung carcinoma) and MDA (breast adenocarci-
noma) lines were negative however.
In order to ensure that the antibody did not cross-react with
topoisomerase IIIb, Western blotting experiments were carried out
against a lysate of yeast EGY48 cells transfected with the
pEG202-topoisomerase IIIb construct. No reactivity of TOPO3a-
1A4 with topoisomerase IIIb was seen, even though blotting with
anti-Lex-A antibody revealed the presence of the topoisomerase
IIIb protein (Figure 2).
Antibody characterization by immunohistochemistry
Analysis by immunohistochemistry was carried out on a range of
neoplastic and non-neoplastic tissues as described below, and
summarized in Table 1 and 2. In all tissues showing positive
immunoreactivity, cells exhibited a diffuse nuclear stain with dot-
like accentuation suggestive of nucleolar localization, most
evident in cases showing lower levels of nuclear staining. There
was no staining of cytoplasm. At all sites, labelling of endothelial
cells and fibroblasts was seen. There was no relationship between
expression and proliferating compartments with the exception of
low grade cervical intra-epithelial neoplasia where the basal layers
showed strongest expression (Figure 4F).
Normal tissues
TOPO3a-1A4 produced moderate to strong immunostaining in
epidermis, cutaneous sebaceous glands, transitional epithelium of
bladder (Figure 3F), cervical glandular and squamous epithelium,
and respiratory epithelium (Figure 3B). In the gastrointestinal tract,
staining was observed in gastric pit cells (but not glands), small
intestinal glandular and villous epithelial cells, and a proportion of
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Figure 1 Western blot showing immunoreactivity of TOPO3a-1A4 in cell
lines. Lanes 1–7 represent HT29, T47D, A431, SKBr3, ZR75, A549 and MDA
cell lysates respectively. A band of around 110 kDa can clearly be seen in
lanes 1–4 (arrow), but expression is not detectable in lanes 5–7
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Figure 2 Western blot showing lack of cross-reactivity with human
topoisomerase IIIb. Lanes 1 and 3 are control yeast lysates (strain EGY48),
lanes 2 and 4 are lysates of an EGY48 clone expressing a Lex A-topoIIIb
fusion protein. There is no reactivity of TOPO3a-1A4 with topoisomerase IIIb,
even though blotting with anti-Lex-A antibody reveals the presence of the
topoisomerase IIIb proteinglandular cells in the large intestine. Pancreatic acinar and duct
cells were positive. Amongst endocrine tissues, labelling was
observed in epithelial cells of thyroid and parathyroid glands, but
not in pancreatic islet cells, and in the adrenal cortex, but not
medulla. In breast tissue, weak staining was seen in lobules
(Figure 3A) and ducts where a proportion of epithelial but not
myoepithelial cells labelled. In the liver most hepatocytes showed
weak nucleolar labelling but bile ducts were negative. In the
kidney, tubules were negative but around 50% of cells in glomeruli
were positive. In bone marrow around 10% of cells showed staining
but it was not possible to determine the lineage involved. In lymph
node and tonsil, staining was observed in most endothelial cells and
sinus histiocytes (Figure 3D); a proportion of paracortical cells
stained weakly but in the germinal centres only occasional cells
labelled, most likely follicular dendritic cells. In the central
nervous system neurons and astrocytes were positive, whilst oligo-
dendrocytes showed slightly weaker labelling. Peripheral auto-
nomic ganglion cells showed strong staining (Figure 3C), and a
small proportion of the Schwann cells of peripheral nerve labelled.
Ovarian specialized cortical stroma was negative; oocytes were
positive. Hofbauer cells of chorionic villi were strongly positive in
contrast to the trophoblast which was negative (Figure 3E).
Testicular germ cells showed staining whereas sertoli cells and
spermatozoa were negative.
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Table 1 Immunostaining for topoisomerase IIIa on a range of normal tissues
System Tissue Cells Staining
Gastrointestinal Pancreas Acinar cells Negative
system Ducts 90% ++
Islets Negative
Stomach (acid secreting Glandular epithelial cells Negative
mucosa) Gastric pit epithelial cells 60%+
Small intestine Glandular epithelial cells 100% +
Villus epithelial cells 100% +
Colon Glandular epithelial cells 50%+
Liver Hepatocytes 100% +
Bile duct epithelium Negative
Reproductive Cervix Mucus glandular epithelium 100% ++
system Squamous epithelium 100% ++
Endometrium Glandular epithelial cells 100% +
Stromal cells 50% +
Ovary Specialised stroma Negative
Oocytes 100% +
Placenta Hofbauer stromal cells 80% +++
Trophoblast Negative
Breast Lobules Epithelial cells 50% +
Myoepithelial cells Negative
Ducts Epithelial cells 90% ++
Myoepithelial cells Negative
Testis Germ cells 50% ++
Sertoli cells Negative
Spermatozoa Negative
Genitourinary Kidney Tubular epithelial cells Negative
system Glomerular cells 50% ++
Bladder Urothelial cells 100% +++
Lymphohaemopoietic Bone marrow Myeloid cells 10% ++
system Lymph node Germinal centre cells 5% ++
Paracortical cells 50% +
Sinus histiocytes 90% +++
Endothelial cells 90% +++
Tonsil Germinal centre cells Negative
Paracortical cells 10% +
Squamous epithelium 50% ++
Integumentary Skin Squamous epithelium (all layers) 100% ++
system Sweat gland epithelium 80% ++
Sebaceous gland epithelium 100% ++
Endocrine Pituitary gland Adenohypophysis 50% +
system Neurohypophysis 90% ++
Parathyroid gland All cells Negative
Thyroid gland Follicular epithelial cells 100% ++
Adrenal gland Cortical cells 50% +
Medullary cells Negative
Nervous system Brain (cerebral cortex) Neurones 100% ++
(central) Astrocytes 100% ++
Oligodendrocytes 100% +
Nervous system Nerve Schwann cells 1% ++
(peripheral) Ganglion cells 100% ++Neoplastic tissues
Considering neoplastic conditions, tumours derived from tissues
normally not showing detectable staining were also negative (islet
cell tumour, phaeochromocytoma) although a small proportion of
cells in a renal carcinoma were labelled (normal renal tubules were
negative). Benign tumours (breast, colon (Figure 4A), thyroid
(Figure 4E), parathyroid, and nerve sheath) showed expression
similar to or greater than their normal counterpart normal tissue
(squamous carcinoma of cervix (Figure 4F), non-melanoma skin
cancer, seminoma, cystadenoma of ovary, papillary carcinoma of
thyroid, endometrial carcinoma). However, some other malignant
tumours (breast carcinoma (Figure 4C), follicular carcinoma of
thyroid, gastric carcinoma (Figure 4D), small cell carcinoma of
bronchus) showed reduced or absent expression. Adenocarcinoma
of colon (Figure 4B) showed expression similar to that of normal
colonic epithelium, but less than that seen in adenoma. Thus inva-
sive malignant lesions showed variable expression, either greater or
less than the tissue of origin. The in-situ neoplasms studied showed
expression similar to that of the epithelium of origin (cervical intra-
epithelial neoplasia, ductal carcinoma in-situ of breast).
DISCUSSION
So far very little information is available regarding expression and
tissue distribution of human topoisomerase IIIa. Our results have
confirmed the suspected wide tissue distribution of the enzyme;
we have shown that the enzyme is expressed in a number of cell
types, and shows the expected nuclear localization. Expression is
also prominent in nucleoli, indicating a possible role in the modu-
lation of the ribosomal genes. We noticed high concentrations of
the enzyme in endothelial and stromal cells of all tissues studied.
Unlike topoisomerase IIa, no relationship was observed
between expression of topoisomerase IIIa and proliferation.
Although widely distributed, a number of cell types in certain
tissues showed no detectable staining by both immunohistochem-
istry and Western blotting. Regarding the former, since endothelial
cells and stromal cells were always stained, this observation
cannot be attributed to non-immunoreactive (e.g. over-fixed)
tissue blocks. However it is possible that topoisomerase IIIa
expression is present at a level not detectable by the techniques
utilized. No obvious pattern has emerged to explain the finding of
reduced or absent labelling in some cells and tissues. Considering
neoplastic tissues, it was generally observed that topoisomerase
IIIa expression paralleled that of the tissue of origin, for example
adrenal medulla and phaeochromocytoma were both negative;
thyroid follicular epithelium and carcinoma were both positive.
However in some cases, expression was somewhat greater in
neoplastic tissues as compared to the tissue of origin; for example
colonic adenoma showed greater expression than normal colonic
epithelium. Of particular interest is the observation of reduced
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Table 2 Immunostaining for topoisomerase IIIa on a range of neoplastic tissues
System Tissue Cells Staining
Gastrointestinal Pancreas Islet cell adenoma Negative
system Stomach Adenocarcinoma Negative
Oesophagus Squamous cell carcinoma. 10% ++
Colon Adenoma 100% ++
Adenocarcinoma 10% +
Reproductive Cervix Cin I 50% ++
system Cin II 50% +++
Cin III 80% +
Squamous cell carcinoma. 80% ++
Endometrium Adenocarcinoma 90% ++
Ovary Cystadeno carcinoma 90% ++
Breast Fibroadenoma 95% ++
Adenoma 60% ++
Papilloma 10% +
DCIS large cell 50% +
ADH 90% ++
Carcinoma 1% +
Testis Seminoma 50% +
Genitourinary Kidney Renal cell carcinoma 10% +
system Bladder Transitional cell carcinoma. 95% +++
Lymphohaemopoietic Bone marrow ALL 5% +
system Lymphoma Diffuse large B-cell 1% +
Integumentary Skin Basal cell carcinoma 60% +
system Squamous cell carcinoma. 90% +++
Malignant melanoma 90% ++
Endocrine Thyroid gland Adenoma 50% ++
system Follicular carcinoma 50% +
Papillary carcinoma 90% ++
Parathyroid gland Adenoma 10% +
Adrenal gland Phaeochromocytoma Negative
Nervous system Brain Astrocytoma 10% +
(central)
Nervous system Nerve Schwannoma 90% ++
(peripheral) Neurofibroma 50% ++
Respiratory Lung Squamous cell carcinoma. 95% +
system Small cell carcinoma Negative(breast carcinoma, follicular carcinoma of thyroid) or absent
(gastric carcinoma, small cell carcinoma of bronchus) expression
in some malignant neoplasms. Since only a single tumour was
studied in each case, further work is required to determine the
frequency and significance of this finding.
Although very little information exists regarding the possible
function of topoisomerase IIIa in cell metabolism, there is
some evidence linking the enzyme with a role in genome
stability, which is consistent with our demonstration of the
wide tissue distribution of the enzyme. In yeast, topoisomerase
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Figure 3 Immunostaining of normal tissues with TOPO3a-1A4. (A) Breast lobule; a proportion of acinar cells show staining. (B) Bronchus, pseudo-stratified
columnar epithelium; nuclei show nucleolar and diffuse labelling. (C) Peripheral autonomic ganglion; note intense staining of ganglion cell nuclei. (D) Lymph
node, germinal centre; most cells are negative; occasional positive cells may represent follicular dendritic cells; the surrounding paracortex shows weak
labelling of around half the cells. (E) Placenta, chorionic villi; Hofbauer cells within the villi show strong staining in contrast to complete absence in trophoblast.
(F) Bladder, transitional epithelium; note intense staining of all epithelial cells, contrasting with only a few lymphocytes in the submucosaIII mutations result in cells displaying a slow-growth, hyper-
recombinant phenotype. It has been suggested that the former
may occur as the result of a potential role of topoisomerase III
in DNA replication, where, in addition to topoisomerase IIa,
the enzyme would separate replicated chromosomes (Gangloff
et al, 1994).
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Figure 4 Immunostaining of neoplastic tissues with TOPO3a-1A4. (A) Colon adenoma; note strong nucleolar and diffuse nuclear labelling of epithelial cells.
(B) Colon carcinoma; note reduced expression compared to the adenoma, and contrasting with strong staining of stromal fibroblasts. The level of labelling was
comparable to normal colonic epithelium. (C) Breast carcinoma; the tumour shows almost complete absence of detectable labelling, compared to staining of
cells in the normal duct shown on the left. (D) Gastric carcinoma; no evidence of tumour cell labelling, but stromal cells are positive. (E) Follicular adenoma of
thyroid; staining is comparable to normal tissue. (F) Cervical intra-epithelial neoplasia, grade I; note maximal labelling of cells in the basal layersNew monoclonal antibody to human topoisomerase IIIa 505
British Journal of Cancer (2000) 83(4), 498–505 © 2000 Cancer Research Campaign
In yeast, topoisomerase III activity is thought to be closely asso-
ciated with Sgs1, a DNA helicase that also plays a role in genome
stability. It has been suggested that the two may form a complex,
whereby the function of Sgs1 is to melt the DNA duplex,
providing a single-stranded substrate for topoisomerase III. Sgs1
is crucial for maintaining genome stability in yeast, with defective
or deficient strains showing hyper-recombination and slow
growth. Furthermore Sgs1 is a member of the bacterial recQ
family of helicases which also includes the human homologues
BRM and WRN. Mutations in these genes are responsible for the
human conditions Blooms and Werners syndromes, which display
a hyper-recombinant phenotype, with an increased risk of malig-
nancy.
The interaction between topoisomerase III and Sgs1 in yeast has
been reported (Gangloff et al, 1994), but the precise biochemistry
of their association remains unclear. It seems that in cells with
mutant topoisomerase III, a mutation in Sgs1 can actually suppress
the slow growth/hyper-recombinant phenotype associated with
this defect. In addition, the genetic instability associated with
Blooms and Werners syndromes (and also ataxia telangiectasia)
can be at least partially alleviated by a mutation in human topoiso-
merase IIIa (Fritz et al, 1997; Yamagata et al, 1998). It seems
possible that a single mutation in either helicase or topoisomerase
results in cellular defects, whilst mutations in both genes is less
harmful, implying a kind of dominant negative relationship.
An interaction between human topoisomerase type IIIa
enzymes and the BRM and WRN proteins has not yet been
reported, but is strongly suspected. It may be possible to investi-
gate the relationship between these proteins using TOPO3a-1A4
in order to further elucidate mechanisms involved in these
diseases.
The specificity of TOPO3a-1A4 has been demonstrated by
ELISA, Western blotting, and immunohistochemistry. We have
demonstrated wide distribution of the antigen in a variety of
neoplastic and non-neoplastic tissues. Topoisomerase IIIa clearly
shares ubiquitous expression with topoisomerase I, the other
member of the topoisomerase type I family present in humans.
Although a number of reagents have been identified which demon-
strate anti-topoisomerase I activity, to date little work has been
carried out towards identification of topoisomerase IIIa/b
inhibitors. This study represents a wide-ranging overview of
expression in normal and neoplastic tissues, taking a single
example of each. There is some evidence that levels of expression
of topoisomerases may predict response to topoisomerase poisons
– therefore if new or existing reagents are found to target the topo-
isomerase IIIa/b enzymes, it will clearly be of importance to
expand our observations concerning the variability of expression
in certain malignant tumour types, examining larger numbers of
cases and subtypes, and this is the goal of ongoing work in our
laboratory.
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